In another study, compared with PDX SCID mice with wild-type EGFR, TGR and tumor cell dissemination were significantly increased in PDX SCID mice with mutated versions of EGFR after nivolumab therapy (Lo Russo et al., 2019). The gene discussed is EGFR; the disease is neoplasm.